• Vivos Therapeutics filed a certificate on July 7, 2026 creating Series A Convertible Preferred Stock tied to warrants issued in a June 30 PIPE.
• The PIPE included warrants to buy 3,608,496 common shares at an exercise price of $0.46, exercisable immediately with a five-year term.
• Two transferable subscription rights per unit were not issued at closing; issuance is conditioned on SEC effectiveness of a Rights registration statement.
• The company must file a resale registration statement within 45 days to register common shares issuable from preferred conversions and warrant exercises.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-032387), on July 07, 2026, and is solely responsible for the information contained therein.